Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...
MedTech Intelligence

Prodeon Medical FDA 510(k) approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia

The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.
Gizmodo

Experimental Cream Could Make ‘Permanent’ Scars a Thing of the Past

Cool guys may have scars, but plenty of people would relish the opportunity to get rid of their own. In new research out this week, an experimental drug has shown promise at being able to clear up ...
EurekAlert!

Study reveals target for reversing scar tissue after heart attack

BOSTON—A new study by investigators at Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham (MGB) healthcare system, reveals an important step to help the human heart ...